Chimerix (CMRX) Stock Price
Chimerix Price
Revenue at Chimerix has contracted by 13.9% per year over the past 14 years to 212,000.00 USD. For Chimerix, the net margin of -41,692.0% is down versus -784.2% a few years ago. The consensus 12-month price target for Chimerix is 8.72 USD, about 2.1% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
Chimerix stock price
Chimerix business model & stock analysis
Frequently asked questions about Chimerix
Chimerix Inc. operates with a business model focused on the development and commercialization of innovative antiviral therapeutics. The company aims to address unmet medical needs and improve patients' lives through the discovery, research, and development of novel antiviral medications. Chimerix Inc. primarily focuses on developing oral nucleotide analogs that target viral replication and replication pathways, aiming to provide effective treatments for various viral infections. With its commitment to advancing medical science, Chimerix Inc. leverages its expertise to create valuable pharmaceutical solutions, contributing to the advancement of antiviral therapeutics.
Chimerix Inc primarily operates in the biotechnology and pharmaceutical industries.
The main competitors of Chimerix Inc in the market include pharmaceutical companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline.
Chimerix Inc is a pharmaceutical company based in Durham, North Carolina. Founded in 2002, the company primarily focuses on the development and commercialization of innovative antiviral therapeutics. Chimerix has a rich history in the field of antiviral research and has made significant contributions to the medical community. The company's mission is to discover, develop, and deliver novel medicines to improve the lives of patients suffering from life-threatening diseases. With a dedicated team of scientists and researchers, Chimerix continues to advance its pipeline of antiviral drugs, providing hope for patients worldwide.
Chimerix Inc has achieved significant milestones throughout its history. One notable achievement was the successful completion of Phase 3 clinical trials for its antiviral drug, brincidofovir. This marked a crucial milestone in the company's efforts to develop an effective treatment for viral infections, including cytomegalovirus. Additionally, Chimerix Inc has secured multiple partnerships and collaborations with renowned healthcare organizations and research institutions. These partnerships have paved the way for further advancements in Chimerix's drug development pipeline and enhanced its potential to address unmet medical needs. Chimerix Inc continues to strive for further milestones and innovations in the field of antiviral therapeutics.
Chimerix Inc is primarily present in the United States.
Chimerix Inc is a biopharmaceutical company that is committed to improving the lives of patients suffering from life-threatening diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centered care. Chimerix Inc values scientific excellence, integrity, and transparency in all aspects of their operations. They strive to develop novel antiviral therapies to address unmet medical needs. With a dedicated team of experts, Chimerix Inc focuses on delivering innovative solutions that can make a significant impact in the medical field. This commitment to patients, scientific advancement, and ethical practices defines Chimerix Inc and sets them apart in the biopharmaceutical industry.
Analysts currently set an average price target of 8.71 USD for the Chimerix stock (median: 8.72 USD), implying +2.0 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Chimerix stock: 7 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Chimerix to generate revenue of 38.60 M USD and earnings per share of -0.81 USD.
Converted at the current exchange rate, the Chimerix share trades at 7.62 EUR (8.54 USD).
The Chimerix share (CMRX) is listed on 5 stock exchanges, including: NASDAQ (CMRX), SIX (Zürich) (CXF.SW), Frankfurt (CXF.F), München (CXF.MU), Düsseldorf (CXF.DU).
Chimerix Inc is a US biotech company specializing in the development of antiviral and immunoncology therapeutics. It was founded in 2000 and is headquartered in Durham, North Carolina. The company's business model focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases and cancer. Chimerix operates in two main areas: infectious diseases and cancer. In infectious diseases, its leading product is Brincidofovir (BCV) for the treatment of life-threatening virus infections such as cytomegalovirus (CMV) and adenovirus infections. In cancer therapy, Chimerix has multiple products in its pipeline that aim to activate the immune system to fight tumors. The company collaborates with leading academic and clinical research institutions and utilizes various business models to market its products, including partnerships with government-funded research programs and multinational pharmaceutical companies. Overall, Chimerix has a promising pipeline of products in clinical studies and is well-positioned to improve global patient care.
The expected revenue of Chimerix is 38.60 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Chimerix is -73.55 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Chimerix is currently -10.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Chimerix stock.
The price-to-sales ratio (P/S) of Chimerix is currently 19.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Chimerix stock.
The Eulerpool Quality Score for Chimerix is 1/10.
The ISIN of Chimerix is US16934W1062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Chimerix is A1T65B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Chimerix is CMRX. The ticker symbol is used to trade Chimerix shares on the stock exchange.
Chimerix stock
Chimerix Peer Group
Chimerix Ticker
Chimerix FIGI
All fundamentals and in-depth analysis of Chimerix
Our stock analysis for Chimerix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chimerix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.